Non-Small Cell Lung Carcinoma (NSCLC) Market

Future Market Insights

Key Insight

The non-small cell lung carcinoma (NSCLC) market is projected to grow from USD 10.0 billion in 2025 to USD 25.9 billion by 2035, at a CAGR of 10.0%. Adenocarcinoma will dominate with a 42.5% market share, while immunotherapy will lead the treatment segment with a 36.0% share.

August 18, 2025

Anurag Sharma

287 Pages

Cite this Report

Non-Small Cell Lung Carcinoma (NSCLC) Market

https://www.futuremarketinsights.com/reports/non-small-cell-lung-carcinoma-nsclc-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

BlackRock
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene Corporation
Novartis
The Vanguard Group
Sun Pharmaceutical Industries Ltd

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Non-Small Cell Lung Carcinoma (NSCLC) Market

Key Players

Similar Industry Reports